Immunohistochemical detection of CA-125 and carcinoembryonic antigen in ovarian tumors in relation to corresponding preoperative serum levels

Aim. To analyze the recurrence of endometriosis after surgical treatment of patients with deep endometriosis. Materials and methods. The case histories of 90 patients aged 19 to 45 years were retrospectively analyzed. The study group consisted of 70 endometriosis patients: 20 with peritoneal endometriosis and 50 with deep infiltrative endometriosis (DIЕ). The comparison group included 20 women without endometriosis. There was an in-depth study of anamnestic data in the cohort of patients under study. The results of preoperative laboratory tests, including serum levels of the CA-125 and CA 19-9 oncomarkers, were processed. Results. Analysis of the obtained data showed that about half of the DIE patients (54%) in the main group had a history of surgical interventions for endometriosis. The number of operations was significantly higher in patients compared to the peritoneal endometriosis group (68% vs 20%, respectively; р=0.0012). Two subgroups were formed from the group of women with DIE: patients who had no history of previous surgical treatment for endometriosis and those hospitalized for repeated surgical treatment of endometriosis (patients with recurrent endometriosis). Patients with recurrent endometriosis had a significantly higher incidence of heavy menstruation, pregnancy terminations (abortions), and a high proportion of gastrointestinal diseases. Analysis of the hormonal therapy received in patients with DIE showed that every second patient with relapses (18/53%) after surgical treatment and every third patient without a prior history of surgery (5/31%) received hormonal therapy. Examination of the preoperative serum levels of CA-125 and CA 19-9 serum markers in patients with DIE showed an increase in their serum levels and a correlation with the frequency of endometriosis recurrence and the size of DIE foci. Conclusion. Despite the conservative and surgical treatment of DIE patients, the recurrence rate is still high. At present, there is no satisfactory therapy for all endometriosis patients. Therefore, the development of therapy for the conservative treatment of the disease remains an urgent task.

Download Full-text

Preoperative serum levels of the carcinoembryonic antigen in hereditary non-polyposis colorectal cancer compared to levels in sporadic colorectal cancer

Cancer Detection and Prevention ◽

10.1016/j.cdp.2005.04.003 ◽

2005 ◽

Vol 29 (4) ◽

pp. 356-360 ◽

Cited By ~ 5

Author(s):

Uwe Schiemann ◽

Silke Günther ◽

Manfred Gross ◽

Gaby Henke ◽

Yvonne Müller-Koch ◽

...

Keyword(s):

Colorectal Cancer ◽

Carcinoembryonic Antigen ◽

Serum Levels ◽

Sporadic Colorectal Cancer ◽

Preoperative Serum

Download Full-text

Carcinoembryonic Antigen in Gynecologic Cancers. Immunohistochemical Localization and Serum Levels

Tumori Journal ◽

10.1177/030089168306900104 ◽

1983 ◽

Vol 69 (1) ◽

pp. 23-30 ◽

Cited By ~ 1

Author(s):

Józef Kula ◽

Antonina Harlozinska ◽

Roman Richter ◽

Zygmunt Albert ◽

Józef Sward ◽

...

Keyword(s):

Carcinoembryonic Antigen ◽

Genital Tract ◽

Female Genital Tract ◽

Serum Levels ◽

Immunohistochemical Localization ◽

Double Immunodiffusion ◽

Preoperative Serum ◽

Serum Cea ◽

Different Content ◽

Female Genital

The presence of carcinoembryonic antigen (CEA)-dependent fluorescence was observed in almost 89% of female genital tract cancers irrespective of their histologic type. Anti-CEA serum was free of antibody to normal cross-reacting antigen. The high percentage of positive fluorescence tests did not correlate with the preoperative serum CEA levels. Double immunodiffusion tests showed different content of CEA and normal cross-reacting antigen in individual specimens of genital tract cancers.

Download Full-text

Analysis of Metastatic Ovarian Tumors from Extragenital Primary Sites

Tumori Journal ◽

10.1177/030089160609200605 ◽

2006 ◽

Vol 92 (6) ◽

pp. 491-495 ◽

Cited By ~ 23

Author(s):

Taner Turan ◽

Burcu Aykan ◽

Sevgi Koc ◽

Nurettin Boran ◽

Gokhan Tulunay ◽

...

Keyword(s):

Tumor Marker ◽

Primary Tumor ◽

Frozen Section ◽

Ovarian Tumors ◽

Ca 125 ◽

Tumor Site ◽

Primary Tumor Site ◽

Adequate Treatment ◽

Presenting Symptoms ◽

Preoperative Serum

Aims and background The aim of this study was to evaluate patients with metastatic ovarian tumors from extragenital primary sites. Methods The medical records of 75 patients were reviewed retrospectively for age at diagnosis, presenting symptoms, preoperative tumor marker levels, preoperative diagnostic workup, operative technique, intraoperative evaluation, frozen-section and pathology results, laterality of metastasis, and primary tumor site. The specific impact of metastasis from colorectal and gastric primary sites on laterality, gross features and dimensions of ovarian mass, volume of ascites and tumor marker levels was investigated. Results Primary sites were stomach (37.3%), colorectal region (28%), lymphoma (12%), breast (6.7%), biliary system (2.7%), appendix (1.3%) and small intestine (1.3%). It was not possible to identify the primary tumor site in 8 (10.7%) patients. Bilateral metastasis was found in 86.4% patients; 42.7% of the metastatic ovarian tumors were Krukenberg tumors; 50.7% of the ovarian masses were solid. Frozen section was confirmed by postoperative pathological results in 98% of the patients. The mean preoperative serum levels of tumor markers were 298.7 U/mL, 178 U/mL and 113.3 U/mL for CA 125, CA 19-9 and CA 15-3, respectively. CA 125 levels were above 35 U/mL in 81.3% of the patients. The presence of ascites was more frequent in ovarian tumors originating from colorectal and gastric primaries. Conclusions Surgery is essential for the diagnosis of the primary tumor and necessary for relief of symptoms. The identification of the primary site is required to plan adequate treatment.

Download Full-text

Borderline Ovarian Tumors: Fifteen Years’ Experience at a Scottish Tertiary Cancer Center

International Journal of Gynecological Cancer ◽

10.1097/igc.0000000000001364 ◽

2018 ◽

Vol 28 (9) ◽

pp. 1683-1691 ◽

Cited By ~ 6

Author(s):

James May ◽

Karolina Skorupskaite ◽

Mario Congiu ◽

Nidal Ghaoui ◽

Graeme A. Walker ◽

...

Keyword(s):

Malignant Transformation ◽

Surgical Management ◽

Early Stage ◽

Ovarian Tumors ◽

Ca 125 ◽

Ovarian Malignancy ◽

Borderline Ovarian Tumors ◽

Gynecology And Obstetrics ◽

Preoperative Serum

ObjectivesSince the recognition of borderline ovarian tumors (BOTs) in the 1970s, the management of this subset of epithelial ovarian tumors has presented a challenge to clinicians. The majority present at an early stage, but their diagnosis is often only made following surgery, hence the heterogeneity of surgical management. Borderline ovarian tumors are morphologically diverse, and their behavior is subsequently also heterogeneous. We aimed to assess recurrence rates and the rate of malignant transformation in patients diagnosed with BOT. Secondary objectives included a review of current management and assessment of tumor markers, stage, cyst dimensions, and the presence of micropapillary features as prognostic indicators of recurrence.MethodsThis retrospective cohort study included all patients treated with BOT between 2000 and 2015 in the southeast region of Scotland. Clinical, surgicopathological, and follow-up data were collated. Data were analyzed with reference to recurrence and malignant transformation.ResultsTwo hundred seventy-five patients underwent treatment for BOT in the study period. Surgical management was highly variable. A diagnosis of recurrent/persistent BOT or ovarian malignancy following initial treatment of BOT was rare, with only 12 (4%) of 275 cases. There were 7 cases (3%) of ovarian malignancy. Advanced International Federation of Gynecology and Obstetrics stage was the most prominent prognostic factor. Elevated preoperative serum CA-125 and the presence of micropapillary features correlated with advanced stage at presentation. With a lack of clear guidance, follow-up was highly variable with a median of 43 months (0–136 months).ConclusionsTo our knowledge, this study is the largest BOT cohort in the United Kingdom. Recurrent disease is rare in optimally staged, completely resected, early-stage BOT, without high-risk features. Caution is needed in women electing not to undergo completion staging after diagnosis and in those opting for a fertility-preserving approach. Thorough informed consent and clear plans for surveillance and follow-up are needed with consideration of delayed completion surgery as appropriate.

Download Full-text

Surgical Treatment of Metastatic Ovarian Tumors From Extragenital Primary Sites

International Journal of Gynecological Cancer ◽

10.1097/igc.0000000000000673 ◽

2016 ◽

Vol 26 (4) ◽

pp. 688-696 ◽

Cited By ~ 8

Author(s):

Veysel Sal ◽

Fuat Demirkiran ◽

Samet Topuz ◽

Ilker Kahramanoglu ◽

Ibrahim Yalcin ◽

...

Keyword(s):

Prognostic Factors ◽

Residual Disease ◽

Univariate Analysis ◽

Ovarian Metastasis ◽

Ovarian Tumors ◽

Ca 125 ◽

Cancer Site ◽

Primary Cancer ◽

Preoperative Serum ◽

Primary Cancer Site

ObjectiveThe purpose of this study was to investigate the outcomes and prognostic factors of metastasectomy in patients with metastatic ovarian tumors from extragenital primary sites.Materials and MethodsAll patients with pathologically confirmed metastatic ovarian tumors between January 1997 and June 2015 were included in this study. A total of 131 patients were identified. The data were obtained from the patients’ medical records. Clinicopathological features were evaluated by both univariate and multivariate analyses.ResultsThe primary sites were colorectal region (53.4%), stomach (26%), and breast (13%). Preoperative serum CA 125 and CA 19-9 levels were elevated in 29.4% and 39.8% of the patients, respectively. Cytoreductive surgery was performed in 41.2% of the patients. Seventy-three (55.7%) patients had no residual disease after surgery. Sixty-six (49.6%) patients had combined metastases at the time of the surgery to sites including the liver, pancreas, lung, bone, lymph nodes, bladder, or the intestine. With a median follow-up of 33 months, the median survival time was 22 months. The estimated 5-year survival probability is 0.26. On univariate analysis, primary cancer site, combined metastasis outside the ovaries, residual disease, preoperative serum CA 125 and CA 19-9 levels, and histologic type were significant parameters for overall survival. Furthermore, residual disease, preoperative serum CA 19-9 level, and primary cancer site were found to be independent prognostic factors on multivariate analysis.ConclusionsThe most common primary sites for ovarian metastasis are gastrointestinal tract. Metastasectomy may have beneficial effects on survival, especially if the residual disease is less than 5 mm. Prospective studies warranted to evaluate the value of metastasectomy in patients with ovarian metastasis.

Download Full-text

Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: Influence of histological type, grade of differentiation, and clinical stage of disease

Gynecologic Oncology ◽

10.1016/0090-8258(90)90394-z ◽

1990 ◽

Vol 39 (1) ◽

pp. 26-33 ◽

Cited By ~ 32

Author(s):

Bengt Tholander ◽

Adam Taiube ◽

Anders Lindgren ◽

Olof Sjöberg ◽

Ulf Stendahl ◽

...

Keyword(s):

Alkaline Phosphatase ◽

Ovarian Carcinoma ◽

Carcinoembryonic Antigen ◽

Clinical Stage ◽

Serum Levels ◽

Ca 125 ◽

Placental Alkaline Phosphatase ◽

Tissue Polypeptide Antigen ◽

Stage Of Disease ◽

Pretreatment Serum

Download Full-text

Comparison of Serum Tumor Markers for Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma

The American Surgeon ◽

10.1177/000313481007601119 ◽

2010 ◽

Vol 76 (11) ◽

pp. 1210-1213 ◽

Cited By ~ 21

Author(s):

Lian-Yuan Tao ◽

Lei Cai ◽

Xiao-Dong He ◽

Wei Liu ◽

Qiang Qu

Keyword(s):

Hepatocellular Carcinoma ◽

Carcinoembryonic Antigen ◽

Tumor Markers ◽

Intrahepatic Cholangiocarcinoma ◽

High Specificity ◽

Serum Levels ◽

Diagnostic Value ◽

Carbohydrate Antigen ◽

Serum Tumor Markers ◽

Preoperative Serum

Serum tumor markers such as alpha-fetoprotein (AFP), carcinoembryonic antigen, carbohydrate antigen (CA) 19-9, CA242, and CA50 were analyzed to evaluate their diagnostic values in single and combined tests for distinguishing intrahepatic cholangiocarcinoma (ICC) from hepatocellular carcinoma (HCC). Preoperative serum levels of AFP, carcinoembryonic antigen, CA19-9, CA242, and CA50 were measured in 45 ICC and 76 HCC patients. The serum levels and the positive rate of AFP, CA19-9, and CA242 were significantly different between the ICC patients and HCC patients. Although AFP (—) was the most sensitive assay for distinguishing ICC from HCC (91.1%), its specificity was significantly lower than that of CA242 (+) and CA19-9 (+). The combination of AFP (-) and CA242 (+) afforded a high specificity of 94.3 per cent and showed highest accuracy (78.5%). Evaluation of patients without liver cirrhosis also showed similar results. The diagnostic value of CA242 (+) is better than that of CA19-9 (+) and AFP (-) in distinguishing ICC from HCC. Combined detection of AFP (—) and CA242 (+) can improve the specificity and accuracy of diagnosing ICC.

Download Full-text